Day 1 :
Fine Treatment, UK
Keynote: Thermobalancing therapy® and Dr Allen's Devices as an innovative treatment for prostate enlargement, chronic prostatitis and kidney stones
Time : 10:00-10:40
Dr. Allen obtained PhD in Medicine in 1978. For many years he was treated patients with chronic internal diseases, including various kidney problems: nephritis, nephrosis, chronic kidney failure and kidney stones, developing diets for them. Later Dr Allen headed health clinic for the treatment of chronic internal conditions. Then he devoted two decades to further medical research and developed Thermobalancing therapy® and Dr Allen’s Devices for chronic internal diseases, which received a patent in the USA, as “Therapeutic device and method”. He is Director of Fine Treatment, United Kingdom, the Company that distributes these devices worldwide.
Thermobalancing therapy® (TT) and Dr Allen’s therapeutic devices (DATD) provide a side effects free treatment for common chronic urological diseases, such as benign prostatic hyperplasia (BPH), chronic prostatitis and kidney stone disease. TT and DATD received a US patent as “Therapeutic device and method”.
TT is based on a new understanding of the origin of diseases that states that all chronic internal diseases have the same root, the pathological activity of capillaries. As a result of changes in small blood vessels, the focus of hypothermia becomes a continuous trigger in the affected tissue, which gradually increases the pressure in the affected organ that leads to its malfunction.
Therapeutic device applies a natural thermoelement, which accumulates the body heat, to the projection of the affected organ eliminating the focus of hypothermia. For prostate problems thermoelement must be applied to the coccyx area and to dissolve kidney stones 2 thermoelements - to the projection of kidneys. Dr Allen’s Device is a class 1 medical device, so it can be used by everyone at home.
Two clinical trials on TT confirmed its effectiveness. After 6-month use of DATD in 124 men with BPH, the prostate volume (mL) decreased from 45.1 to 31.8 and urinary symptoms score - from 14.3 to 4.7. In men with chronic prostatitis, after 6-month use of DATD pain reduction ranged from 10.3 to 3.5, and prostate volume (mL) from 31.7 to 27.0. There were no changes in the control groups. Thus, TT is an effective tool for urological conditions.
Yale School of Medicine-Yale University, USA
Keynote: Renal outer medullary potassium channel knockout models reveal bartter’s syndrome and dysfunction of potassium homeostasis
Time : 10:40-11:20
Tong Wang completed her M.D. and clinical trainings at Beijing University, School of Medicine in China. She then spent two postdoctoral training periods in the United States, first at the University of Illinois at Chicago and later at Yale University School of Medicine (with Dr. Gerhard Giebisch). Currently, she is a full Professor, Director of the Small Animal Physiology Core in the Department of Cellular and Molecular Physiology and is co-Director of the Renal Physiology Core in the George M O'Brien Kidney Center at Yale University. She has published more than 100 papers in reputed journals and has been serving as an active member of NIH KMBD study section
The renal outer medullary potassium channel (ROMK) is an ATP-sensitive inward-rectifier potassium channel (Kir1.1 or KCNJ1) highly expressed in the kidney. We have demonstrated that ROMK -/- mice show a similar phenotype to Bartter’s syndrome of salt wasting and dehydration due to reduced Na-K-2Cl-cotransporter activity in the thick ascending limb (TAL). Patch clamp studies showed that ROMK is required to form both the small-conductance (30-pS, SK) K and the 70-pS (IK) K channels in the kidney. At least three ROMK isoforms have been identified in the kidney; however, unique functions of any of the isoforms in nephron segments are still poorly understood. We have generated a mouse deficient only in ROMK 1 by selective deletion of the ROMK 1-specific first exon using an ES cell Cre-LoxP strategy and examined the renal phenotypes, ion transporter expression, ROMK channel activity and localization under normal and high K intake. Unlike ROMK -/- mice, there was no Bartter’s phenotype with reduced NKCC2 activity and increased NCC expression in ROMK1-/- mice. The SK activity showed no difference of channel properties or gating in the collecting tubule (CCD) between ROMK1+/+ and ROMK1-/- mice. High K intake increased SK channel number per patch and the ROMK channel intensity in the apical membrane of the CCD in ROMK1+/+, but such regulation was diminished with significant hyperkalemia in ROMK1-/- mice. These results are consistent with previous studies that ROMK1 does not localize in the TAL, and that ROMK1 is a key target of PTK-mediated ROMK trafficking in response to K+ intake.
West Virginia University, USA
Time : 11:40-12:20
Dr. Mohamad W. Salkini, is an Associate Professor of Urology and Chief of Urologic Oncology. He also is dirctor of simulation and robotic Surgery programs at West Virginia University.
Mohamad W. Salkini earned his MD from Damascus University in 1998, and completed urology residency at Damascus University Urology Residency Program in 2003. He was fellow with Heidleberg University and University of Cininnati for the years 2003-2004 and 2007-2009 respectively. He served as research fellow with University of Arizona from 2004-2007.
Percutaneous Nephrolithotripsy (PCNL) is considered the standard treatment for large kidney stone (>2 cm) and large stone burdon. However, and in certain patients, the technique can be challenging and fails. We utilized the da Vinci® surgical robotic system to remove kideny stone in certain circumstansis. Robotic assisted laparoscopic pyelolithotomy (RALPL) was performed at our institute to treat large kidney stones (>2 cm) in morbidly obese patient (BMI >35), patients with skelital deformity that prevent percutaneous access to the kidney or positioning for the access, and after PCNL failure. We, also, performed RALPL whenever the robotic system was used for other perpose like pyeloplasty, partial nephrectomy, utereal reconstruction on the same kidney. RALPL allowed us to utilize other endoscopic intruments to achieve high rate of stone clearance.
Seventeen patients underwent RALPL at our institute including 19 renal units. Average BMI in all patients was 38.5 kg/m2 (range 17.7-61.4 kg/m2), and all had prior abdominal surgeries The indication for RALPL was morbid obesity (n=8, mean BMI 56.4 kg/m2¬), need for concurrent renal surgery (n=3), severe contractures limiting positioning for retrograde endoscopic or percutaneous nephrolithotripsy (n=2), symptomatic calyceal diverticular stone with failed endoscopic approach (n=2) and patient preference over percutaneous nephrolithotripsy after failed PCNL (n=2). Patients had a mean of 2.3 stones and total stone volume of 16.5 cm3 (range 0.7-75 cm3) per kidney. Average blood loss was 57.8 mL and mean operative time was 180 minutes. Mean hospital stay was 3.5 days. Mean follow-up was 54 days and 91 % of patients were rendered stone free.